Cystic Fibrosis Research Fund Inc (EIN 453768161) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1987

Legal Domicile

Principal Officer

Michael Golinkoff

Phone

2153416720

Tax Period

2025-01-01 to 2025-12-31

Cystic Fibrosis Research Fund Inc, founded in 1987, is a community nonprofit in the Diseases & Disorders sector that reported $3.0M in total revenue in fiscal year 2025. Revenue decreased 12% compared to the prior year. Expenses of $2.8M left a modest 9% surplus.

Mission

Research and drug development for the 10 of the cystic fibrosis community that do not benefit from the currently available mutation-targeted therapies.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $2,953,840

Program Service Revenue $0

Investment Income $207,704

Other Revenue $-128,256

TOTAL REVENUE $3,033,288

Expense Breakdown

Grants Paid $1,270,594

Salaries & Benefits $823,516

Fundraising Expenses $268,933

Program Expenses $2,302,449

Other Expenses $668,499

TOTAL EXPENSES $2,762,609

Year-over-Year Comparison

	2025	2024	Change
Revenue	$3,033,288	$3,451,167	-0.1%
Expenses	$2,762,609	$2,959,423	-0.1%
Net Income	$270,679	$491,744	-0.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Greg Reh	Director	000.50	Director	$0	$0	$0
Jessica Rutstein Lazarus	Director	000.50	Director	$0	$0	$0
Beth Shapiro Lavin	Director	002.00	Director	$0	$0	$0
Julie Wertheimer	Director	000.20	Director	$0	$0	$0
Coby Kramer Golinkoff	Director	005.00	Director	$0	$0	$0
Danielle Selber	Director	000.50	Director	$0	$0	$0
Doug Young	Director	000.20	Director	$0	$0	$0
Nickie Boston	Director	001.00	Director	$0	$0	$0
Emily Kramer Golinkoff	Director	010.00	Director	$0	$0	$0
Nick Dinges	Director	001.00	Director	$0	$0	$0
Joan Denenberg	Director	002.00	Director	$0	$0	$0
Michael Golinkoff	President	010.00	Officer Director	$0	$0	$0
Elizabeth Kramer	Secretary	020.00	Officer Director	$0	$0	$0
Nancy Astor Fox	Director	000.20	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$3,033,288	$2,762,609	$5,622,025	$270,679
2024	$3,451,167	$2,959,423	$5,958,828	$491,744
2023	$2,799,957	$2,119,809	$5,004,389	$680,148
2022	$1,789,652	$1,954,560	$4,247,786	$-164,908
2021	$2,091,732	$943,930	$4,381,158	$1,147,802
2020	$2,042,398	$1,169,291	$3,196,742	$873,107
2019	$2,089,368	$1,071,094	$2,308,993	$1,018,274
2018	$1,448,059	$1,282,787	$1,279,930	$165,272

Cystic Fibrosis Research Fund Inc